Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Suppressor of cytokine signaling 3
(
SOCS3
) plays crucial roles in JAK/STAT signaling pathway inhibition in hepatocellular carcinoma (HCC). However, the methylation status of
SOCS3
in HBV infection-related HCC and the relationship between
SOCS3
methylation and the clinical outcome remain unknown. Here, we reported that in HCC tumor tissues, two regions of the CpG island (CGI) in the
SOCS3
promoter were subjected to methylation analysis and only the region close to the translational start site of
SOCS3
was hypermethylated. In HCC tumor tissues,
SOCS3
showed an increased methylation frequency and intensity compared with that in the adjacent non-tumor tissues. Moreover,
SOCS3
expression was significantly down-regulated in HCC cell lines and tumor tissues, and this was inversely correlated with methylation. Kaplan-Meier curve analysis revealed that in patients with an
hepatitis B
virus (HBV) infection background,
SOCS3
hypermethylation was significantly correlated with a poor clinical outcome of HCC patients. Our findings indicated that
SOCS3
hypermethylation has already happened in non-tumor tissues and increased in both frequency and intensity in tumor tissues. This suggests that the methylation of
SOCS3
could predict a poor prognosis in HBV infection-related HCC patients.
...
PMID:SOCS3 Methylation Predicts a Poor Prognosis in HBV Infection-Related Hepatocellular Carcinoma. 2639 82